|
Volumn 21, Issue 2, 2011, Pages 419-423
|
Definitions for response and progression in ovarian cancer clinical trials incorporating recist 1.1 and CA 125 agreed by the gynecological cancer intergroup (GCIG)
a,p b c d e f g h i j k l m n o
d
HÔTEL DIEU
(France)
|
Author keywords
CA 125; Clinical trials; Ovarian cancer; Progression; RECIST; Response
|
Indexed keywords
CA 125 ANTIGEN;
CANCER GROWTH;
CANCER RECURRENCE;
CLINICAL TRIAL (TOPIC);
EVALUATION;
GYNECOLOGICAL CANCER INTERGROUP;
HEALTH CARE ORGANIZATION;
HUMAN;
MAINTENANCE THERAPY;
OVARY CANCER;
PRIORITY JOURNAL;
RESPONSE EVALUATION CRITERIA IN SOLID TUMOR;
REVIEW;
TREATMENT RESPONSE;
ANTINEOPLASTIC AGENTS;
CA-125 ANTIGEN;
CLINICAL TRIALS AS TOPIC;
DISEASE PROGRESSION;
DISEASE-FREE SURVIVAL;
FEMALE;
HUMANS;
NEOPLASM RECURRENCE, LOCAL;
OVARIAN NEOPLASMS;
|
EID: 79956076619
PISSN: 1048891X
EISSN: 15251438
Source Type: Journal
DOI: 10.1097/IGC.0b013e3182070f17 Document Type: Review |
Times cited : (512)
|
References (6)
|